Enteralia Bioscience has exclusive U.S. and Canadian rights to the biopharmaceutical assets of Nemysis Ltd. We are focused on biopharmaceutical solutions that can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.
· Enteralia's novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and Anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled repeat-dose clinical trials.
· Enteralia's novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.
Company Details
- Founded
- -
- Address
- Iron Deficiency/anemia And Celiac Disease/gluten Intolerance
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Dublin.
Enteralia Bioscience Questions
Enteralia Bioscience's website is https://enteralia-bioscience.com/
Enteralia Bioscience's LinkedIn profile is https://www.linkedin.com/company/enteralia-bioscience
Enteralia Bioscience's industry is
Biotechnology Research
Enteralia Bioscience's top competitors are
Enteralia Bioscience Italia,
Rebel Medicine,
Sethera Therapeutics,
Quansys Biosciences,
Alentic Microscience Inc.,
Matrubials Inc.,
Nemysis Ltd,
Induction Bio,
Avia Pharma Ab,
Juniper Genomics.
Enteralia Bioscience's categories are Biotechnology Research
Enteralia Bioscience's founding year is 2021
